Treatment of metastatic colorectal cancer in the elderly

Cancer and Chemotherapy Reviews

Volumn 6, Issue 3, 2011, Pages 123-132

  Emperador, Pilar Escudero ^a   Marques, Eduardo Polo ^b   Orduña, Vicente Alonso ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Chemotherapy; Colorectal cancer; Elderly; Geriatric assessment score; Liver resection; Metastatic

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RALTITREXED; TEGAFUR; URACIL;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; CREATININE CLEARANCE; DETOXIFICATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; ELDERLY CARE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GERIATRIC ASSESSMENT; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; INJECTION SITE REACTION; KIDNEY FUNCTION; LIVER FUNCTION; LIVER METASTASIS; LIVER RESECTION; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; POLYPHARMACY; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 81355123603     PISSN: 1885740X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2009. CA Cancer J Clin. 2009;25:25.
2. Muss H. Older age not a barrier to cancer treatment. N Engl J Med. 2001;345:1128-9.
3. US Census Bureau: US interim projections by age, sex, race, and Hispanic origin. Available at: http://www.census.gov/popest/estimates.html. 2009.
4. Yancik R. Population aging and cancer: a cross-national concern. Cancer. 2005;11:437-41. (Pubitemid 43097070)
5. National Center for Health Statistics. Health, United States, 2006. Available at http://www.cdc.gov/nchs/data/hus/hus06.pdf; accessed March 25, 2008.
6. Sargent D, Wieand S, Benedetti J, et al. Disease-free survival (DFS) vs. OS (OS) as a primary endpoint for adjuvant colon cancer studies: individual patient data from 12,915 patients on 15 randomized trials. J Clin Oncol. 2004;23: [abstract 3502].
7. Sanoff HK, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. J Clin Oncol. 2007;25:1891-7. (Pubitemid 46854423)
8. Kelly H, Goldberg R. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol. 2005;23: 4553-60. (Pubitemid 46196586)
9. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 2005;11:461-73. (Pubitemid 43097073)
10. Hurria A, Lichtman SM. Pharmacokinetics of chemotherapy in the older patient. Cancer Control. 2007;14:32-43. (Pubitemid 46168964)
11. Wedding U, Honecker F, Bokemeyer C, et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control. 2007; 14:44-56. (Pubitemid 46168965)
12. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344:1111-16. (Pubitemid 32285231)
13. Lichtman SM. Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol. 2006; 3:86-93. (Pubitemid 43250429)
14. Bailey C, Corner J, Addington-Hall J, et al. Treatment decisions in older patients with colorectal cancer: the role of age and multidimensional function. Eur J Cancer Care (Engl). 2003;12:257-62. (Pubitemid 37249096)
15. Feliu J, Sereno M, De Castro J, Belda C, Casado E, González- Barón M. Chemotherapy for colorectal cancer in the elderly: Who to treat and what to use. Cancer Treat Rev. 2009;35:246-54. *An excellent review of all aspects to take into account in decisionmaking in the treatment of elderly patients with metastatic colorectal cancer.
16. Gosney MA. Clinical assessment of elderly people with cancer. Lancet Oncol. 2005;6:790-7. (Pubitemid 41430720)
17. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the international society of geriatric oncology. Crit Rev Oncol Hematol. 2005;55:241-52. *Geriatric assessment is essential before beginning any chemotherapy treatment in elderly patients with metastatic colorectal cancer. This paper specifies the geriatric assessment scales most commonly used. (Pubitemid 41219694)
18. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224-37. (Pubitemid 30429942)
19. Carreca I, Balducci L, Extreman M. Cancer in the older person. Cancer Treat Rev. 2005;31:380-402. (Pubitemid 41430692)
20. Sargent D, Goldberg R, Jacobson S, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in older patients. N Engl J Med. 2001;345:1091-7.
21. Goldman D, Lewis JL, Kilgore ML, et al. The participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383-9. (Pubitemid 46606420)
22. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil- based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15:1330-8. (Pubitemid 39302467)
23. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17:2412-18. (Pubitemid 29368240)
24. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol. 2005;23:3104-11.*One of the few prospective studies with capecitabine monotherapy in elderly patients, endorsing the results obtained with identical treatment in younger patients. (Pubitemid 46224134)
25. Cripps M, Vincent M, Jonker D, et al. Dose reduced first-line capecitabine (Xeloda-TM) monotherapy in older and less fit patients with advanced colorectal cancer. J Clin Oncol. 2005;23: [abstract 3577].
26. Stein BN, Petrelli NJ, Dougass HO, et al. Age and sex are independent factors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer. 1995;75:11-7.
27. Köhne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13:308-17. (Pubitemid 34704985)
28. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5- fluorouracil/leucovorin. Ann Oncol. 2002;13:566-75. (Pubitemid 34461140)
29. Feliu J, Mel JR, Camps C. et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. Eur J Cancer. 2002;38:1204-11. (Pubitemid 34603481)
30. Sastre J, Puente J, García-Saenz JA, Díaz-Rubio E. Irinotecan in the treatment of elderly patients with advanced colorectal cancer. Crit Rev Oncol Hematol. 2008;68:250-5.*Study that after geriatric assessment evaluates the pharmacokinetics and efficacy of irinotecan monotherapy, noting that fit elderly patients get the same benefit without greater toxicity than younger patients.
31. Chau I, Norman A, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer. 2004;91:1453-8. (Pubitemid 39486347)
32. Rosati G, Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori. 2006;92:290-4. (Pubitemid 44525304)
33. Fuchs C, Moore M, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21:807-14. (Pubitemid 46606439)
34. Rothenberg ML, Cox JV, De Vore FR, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999;85:786-95. (Pubitemid 29077554)
35. Rougier P, Mitry E, Cunningham D, et al. Is age a prognostic factor of toxicity and efficacy in patients with metastatic colorectal cancer receiving irinotecan in combination with 5FU/folinic acid (FA). J Clin Oncol. 2003;21: [abstract 1072].
36. Schaaf L, Ichpurani N, Elfring G, et al. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G) in patients with previously treated colorectal cancer. J Clin Oncol. 1997;15: [abstract 708].
37. Saltz LB, Cox JV, Blande C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343:905-14.
38. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. (Pubitemid 38944402)
39. Thomas M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nursing. 2005; 9:1092-5.
40. Bouchahda MT, Macarulla T, Spano JP, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008;67:255-62.
41. Sastre J, Aranda E, Gravalos C, et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol. 2011; 77:78-84.
42. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy - refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-64. (Pubitemid 46797944)
43. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/Fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2691 patients in randomized controlled trial. J Clin Oncol. 2008;26:1443-51.
44. Mitry E, Douillard JY, Van Cutsem E, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol. 2004;15:1013-17. (Pubitemid 39089776)
45. Sastre J, Marcuello E, Massuti B, et al. Irinotecan in combination con fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer. A Spanish Cooperative group for the treatment of digestive tumors study. J Clin Oncol. 2005;23:3545-51.*The larger prospective study in elderly patients evaluated the combination of Irinotecan with 5-FU in the first-line treatment in metastatic colorectal cancer, with results equivalent to those of younger patients.
46. Souglakos J, Pallis A, Kakolyris S, et al. Combination of irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer. A phase II trial. Oncology. 2005;69:384-90. (Pubitemid 41797914)
47. Francois E, Berdah J, Chamorey E, et al. Use of the folinic acid/5- fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a phase II study. Cancer Chemother Pharmacol. 2008;62:931-6.
48. Aparicio T, Jouve J, Teillet L, et al. Geriatric factors to predict toxicity and dose-intensity reduction in FFCD 2001-02 phase III study comparing a first-line chemotherapy of LV5FU2 or FOLFIRI in treatment of metastatic colorectal cancer (mCRC) in elderly patients. J Clin Oncol. 2001;29: [abstract 9111].
49. Bollina R, Beretta G, Toniolo D, et al. Capecitabine and irinotecan (CAPIRI): A good combination in elderly patients (pts) with advanced colorectal cancer (ACRC) as first line chemotherapy (CT). Preliminary results of a phase II trial. J Clin Oncol. 2003;22: [abstract 1332].
50. García Alfonso P, Muñoz-Martin A, Mendez-Ureña M, et al. Capecitabine in combination with irinotecan (XELIRI) administered as a 2-weekly schedule, as first line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer. 2009;101:1039-43.
51. Tabah-Fisch I, Maindrault-Goebel F, Benavides M, et al. Oxaliplatin/5FU/LV is feasible, safe and active in elderly colorectal cancer patients. J Clin Oncol. 2002;21: [abstract 556].
52. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085-91. *Retrospective analysis of 614 patients over 70 years with colorectal cancer treated with oxaliplatin- based chemotherapy, which notes that such schemes maintain their safety and efficacy in selected elderly patients.
53. Sastre J, Aranda E, Massuti B, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol. 2009;70:134-44.
54. Mattioli R, Massacesi C, Recchia F, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/ leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol. 2005;16:1147-51. (Pubitemid 41418318)
55. Kim JH, Oh DY, Kim YJ, et al. Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J Korean Med Sci. 2005;20:806-10.
56. Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer. 2007; 110:2666-71. (Pubitemid 350250335)
57. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Cancer. 2005;104:282-9.
58. Twelves C, Butts C, Cassidy J, et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer. 2005;5:101-7.
59. Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006;94:969-75.*This prospective study evaluates the efficacy of XELOX in firstline treatment of metastatic colorectal cancer in the elderly, which shows an acceptable efficacy with no significant increase in toxicity, which may represent a good alternative for elderly patients who are given a combination treatment.
60. Comandone A, Pochettino P, Bergnolo P, et al. Capecitabine and oxaliplatin: a phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer. J Clin Oncol. 2005;23: [abstract 3681].
61. Seymour MT, Maughan TS, Wasan HS, et al. Capecitabine and oxaliplatin in elderly and/or frail patients with metastatic colorectal cancer: the FOCUS2 trial. J Clin Oncol. 2007;25: [abstract 9030].
62. Cassidy J, Saltz LB, Giantonio BJ, et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010; 136:737-43.*Retrospective analysis of more relevant randomized trials including bevacizumab in metastatic colorectal cancer, which shows that elderly patients benefit as much as the younger from the addition of bevacizumab to chemotherapy, with an increase of thromboembolic events, to the expense of arterial thromboembolic events.
63. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99:1232-9 (Pubitemid 47299901)
64. Kozloff MF, Berlin J, Flynn PJ, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving Bevacizumab and chemotherapy: results from the BRITE observational cohort study. Oncology. 2010;78:329-39.
65. Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer. 2010;102:1468-73.
66. Vrdoljok E, Omrcen T, Boban M, Hrabar A. Phase II study of Bevacizumab in combination with Capecitabine as first line treatment in elderly patients with metastatic colorectal cancer. Anticancer Drugs. 2011;22:191-7.
67. st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer: a pooled analysis of the CRYSTAL and OPUS studies. Ann Oncol. 2010;21: [abstract 597].
68. Rivera F, Gravalos C, Massuti B, et al. Cetuximab plus capecitabine as first-line treatment for elderly patients with advanced colorectal cancer. Final analysis of activity and survival according to K-ras status- the TTD 06-01 Spanish Cooperative Group trial. Eur J Cancer. 2009;(Suppl 7): [abstract 216].
69. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125-35.
70. Adam R, Frilling A, Elias D, et al. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010;97:366-76. *This study evaluated the outcome of liver surgery for colorectal metastases in 1624 patients over 70 years old in a large international multicentre cohort. In this age subgroup, liver resection for colorectal metastases can achieve a reasonable 3-year survival rate, with an acceptable morbidity rate, so it should not be an upper age limit to perform; however, there are some risk factors that can help us to predict potential benefit.
71. Fong Y, Blumgart LH, Fortner JG, et al. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg. 1995;222:426-34.
72. Robertson DJ, Stukel TA, Gottlieb DJ, et al. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer. 2009;115:752-9.